SLC5A2 and heart failure: In addition, it appears reasonable that individuals with OSA and concomitant heart failure, across the wide range of left ventricular ejection fraction, may benefit from treatment with SGLT2 inhibitors, due to their multiple, pleiotropic benefits, regardless of baseline glycemic control or concurrent T2D status.